Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214084 | 1.00 | POLB (0.47) | POLBP2RY6P2RY14NT5EABL1 | |
| SCHEMBL16214082 | 0.88 | P2RY6 (0.46) | POLBP2RY6P2RY14NT5EABL1 | |
| SCHEMBL16214939 | 0.85 | POLB (0.47) | POLBP2RY6P2RY14NT5EABL1 | |
| SCHEMBL15281797 | 0.85 | POLB (0.47) | POLBP2RY6P2RY14NT5EABL1 | |
| SCHEMBL15249240 | 0.82 | POLB (0.39) | POLBP2RY6P2RY14NT5EP2RY12 | |
| SCHEMBL16214139 | 0.82 | POLB (0.39) | POLBP2RY6P2RY14NT5EP2RY12 | |
| SCHEMBL16214085 | 0.82 | POLB (0.39) | POLBP2RY6P2RY14NT5EP2RY12 | |
| SCHEMBL16214125 | 0.80 | P2RY6 (0.45) | POLBP2RY6P2RY14NT5EABL1 | |
| SCHEMBL16214157 | 0.80 | POLB (0.42) | POLBP2RY6P2RY14NT5EABL1 | |
| SCHEMBL16373883 | 0.80 | POLB (0.49) | POLBP2RY6P2RY14NT5EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-9346848-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8877731-B2 | Azido nucleosides and nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264610-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | POLB 954/4885P2RY6 100/4885P2RY14 106/4885 |
| US-20120070415-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | POLB 954/4885P2RY6 100/4885P2RY14 106/4885 |
| US-20150183819-A1 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS | PNP, ADA, ADAR | POLB 954/4885P2RY6 100/4885P2RY14 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.